First Tracks reports positive early-stage results for celiac drug ANB033

First Tracks Biotherapeutics announced that its experimental celiac disease drug ANB033 showed statistically significant improvement in a six‑week early‑stage trial compared with placebo. The trial measured how well the therapy protected the intestinal lining from gluten‑induced damage and found a clear benefit.

In addition to the primary endpoint, ANB033 performed well on secondary measures of disease severity and prevented symptom worsening during a controlled gluten challenge. No serious adverse events were linked to the drug, and no participants discontinued because of side effects.

The company plans to release data from a second cohort in the first quarter of next year and aims to begin a late‑stage trial in 2027, positioning ANB033 as a potential "pipeline‑in‑a‑product" candidate for celiac disease treatment.